Miltefosine and cutaneous leishmaniasis

Current Opinion in Infectious Diseases

Volumn 25, Issue 2, 2012, Pages 141-144

  Machado, Paulo R L ^a   Penna, Gerson ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

cutaneous leishmaniasis; diffuse cutaneous leishmaniasis; disseminated leishmaniasis; miltefosine; mucosal leishmaniasis

Indexed keywords

ANTILEISHMANIAL AGENT; MEGLUMINE ANTIMONIATE; MILTEFOSINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BRAZIL; COLOMBIA; DIARRHEA; DIFFUSE CUTANEOUS LEISHMANIASIS; DISSEMINATED LEISHMANIASIS; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; IRAN; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; NAUSEA; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN LEISHMANIASIS; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VENEZUELA; VOMITING;

ADMINISTRATION, ORAL; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEISHMANIASIS; PHOSPHORYLCHOLINE;

EID: 84858009007     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283509cac     Document Type: Review

References (20)

1. Dummer R, Krasovec M, Roger J, et al. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. J Am Acad Dermatol 1993; 29:963-970. (Pubitemid 23360329)
2. Sindermann H, Croft SL, Engel KR, et al. Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol 2004; 193:173-180. (Pubitemid 40063681)
3. Escobar P, Matu S, Marques C, Croft SL. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop 2002; 81:151-157. (Pubitemid 34093805)
4. Schmidt-Ott R, Klenner T, Overath P, Aebischer T. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1999; 93:85-90. (Pubitemid 29123731)
5. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-1746. (Pubitemid 35375612)
6. Soto J, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33:e57-e61. The first clinical trial evaluating miltefosine in cutaneous leishmaniasis and comparing different schedules.
7. Soto J, Arana BA, Toledo J, et al. Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266-1272. (Pubitemid 38608569)
8. Soto J, Rea J, Balderrama M, et al. Short report: efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78:210-211. (Pubitemid 351844550)
9. Vélez I, López L, Sánchez X, et al. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:351-356. A well designed clinical trial showing that meglumine antimoniate was superior to miltefosine in treating cutaneous leishmaniasis in Colombia.
10. Machado P, Ampuero J, Guimarães LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010; 4:e912. The first clinical trial evaluating miltefosine efficacy and safety in L. braziliensis disease in Brazil.
11. Chrusciak-Talhari A, Dietze R, Talhari CC, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania Viannia guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011; 84:255-260. Miltefosine was superior to meglumine antimoniate in the first clinical trial conducted in cutaneous leishmaniasis caused by L. guyanensis.
12. Mohebali M, Fotouhi A, Hooshmandb B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007; 103:33-40. This clinical trial shows that miltefosine can be useful in the treatment of Old World cutaneous leishmaniasis. (Pubitemid 47078934)
13. van Thiel PP, Leenstra T, Kager PA, et al. Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 2010; 50:80-83.
14. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44:350-356. This is the only study evaluating the efficacy of miltefosine in mucosal leishmaniasis, a hard to treat disease. (Pubitemid 46147616)
15. Zerpa O, Blanco B, Kannee C, et al. Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report. Int J Dermatol 2006; 45:751-753. (Pubitemid 44056682)
16. Calvopina M, Gomez EA, Sindermann H, et al. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg 2006; 75:1074-1077. (Pubitemid 351627483)
17. Zerpa O, Ulrich M, Blanco B, et al. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 2007; 156:1328-1335. This is the largest cohort of DCL patients treated with miltefosine. (Pubitemid 47029811)
18. Schraner C, Hasse B, Hasse U, et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 2005; 40:e120-e124.
19. González LM, Vélez ID. Miltefosine for disseminated leishmaniasis. Biomedica 2006; 26 (Suppl 1):13-16.
20. Alborzi A, Pouladfar GR, Fakhar M, et al. Case report: isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran. Am J Trop Med Hyg 2008; 79:435-437.